Tissue-based biomarkers, including the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), have been integral in subtyping of tumours, prognostication, and choice of systemic therapies. This evidence concerns the gene ERBB2 and neoplasm.